the target depended on the recipient diagnosis. Collection efficiency was evaluated as [total number CD34+ cells in product/(peripheral blood CD34+ cell count x blood volume processed)]. Pre-apheresis WBC and CD34+ measurements were not significantly different. The implementation of Spectra Optia in auto-HCT recipients increased the CD34+ CE2 from 31.2% to 50.1% compared to Cobe Spectra, and from 24.4% to 41.3% in allo-HCT donors. This translated in significantly lower volumes of blood processed to obtain an equal CD34+ dose (Table I ). In addition, MNC CE2 significantly increased and median Hct in the product decreased on Spectra Optia, indicating a higher purity of the collected product. Moreover, we witnessed an increase of the CD34+ collection efficiency on Spectra Optia in years 2014 versus 2013, indicating a learning curve was inherent to the implementation. Our study shows that the integration of MNC collections on Spectra Optia greatly increased efficiency of CD34+ cell collection in comparison to the Cobe Spectra. Consequently, lower blood volumes were processed to obtain equal to better CD34+ cell dose. These results invite to assess further the impact of implementation of Spectra Optia on the number of collection days. and LMP2 which can serve as potential targets for immunotherapy. For many patients with chronic active EBV (CAEBV) and/or relapsed EBV+ Non Hodgkin Lymphoma (NHL) or Hodgkin Lymphoma (HL) the only potential curative option is allogeneic hematopoietic stem cell transplant (allo-HSCT). However, relapse rates remain high (>50%) and the risk of inducing graft versus host disease (GvHD) after DLI limits the broad application of this approach. We hypothesized that the administration of donor-derived cytotoxic T lymphocytes (CTLs) directed to LMP1/2 (LMP-CTL) would rapidly restore LMP-specific T-cell immunity and prevent relapse in these high-risk patients without increasing the incidence of GvHD. LMP-CTLs were expanded using donor monocytes and EBV transformed lymphoblastoid cell lines, transduced with an adenoviral vector encoding either LMP2 (n¼4) or DLMP1 and LMP2 (n¼11).
Characterization of CTL lines at cryopreservation revealed CD4+ and CD8+ cells which were predominantly effector and effector memory phenotype. CTL lines had LMP2 (+/-LMP1) specific activity as determined by ELISPOT and cytotoxicity assays. Fifteen patients (n¼5 HL, n¼4 B-cell CAEBV/NHL, n¼6 T-cell CAEBV/NHL) received 2 infusions of CTLs (dose range: 0.4-3x10e8/m 2 ) approximately 100 days post HSCT. No immediate toxicities related to CTL infusions were observed. Infusion of LMP-CTLs resulted in a maximum 2.5 fold increase in the frequency of LMPs precursors as detected by IFNg eliSPOT assay. No patient developed de novo GVHD post CTLs. GVHD was seen in 4 patients with a pre-existing history (1 patient with DLBCL experienced grade II skin GvHD controlled with steroids, 2 patients (1 NK-T and 1 HL) showed signs of grade I GvHD promptly controlled with steroids. One patient with DLBCL developed grade III GvHD after weaning immune suppression and subsequently developed sepsis and died 10 months after an HLA matched-unrelated HSCT). 13 patients were in remission at the time of CTL infusion and 12/13 of these patients remained in remission for a median of 30 months post CTLs (range 6-90 months). One patient with NK/T cell NHL relapsed 6 months post CTLs and died of progressive disease. Two patients (1HL and 1 T-cell CAEBV) received CTLs for relapsed disease after HSCT and both died of disease. Disease progression in the patient with HL, was likely due to immune-escape since tumor biopsies obtained post CTL were EBV-negative. In conclusion, donor-derived LMPCTLs seem to be well tolerated in high-risk patients with CAEBV and/or EBV+ lymphoma post HSCT. Furthermore, the use of donor-derived tumor-directed T-cells as adjuvant therapy post HSCT may restore LMP-specific T-cell immunity and prevent relapse in this high-risk patient population. 
